Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 36 of the 37 references it cites were found in a registry or an index; 1 of the 10 sources its claims cite were checked for support.

GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs

Open access

Abstract

Background: A meta-analysis is presented of cardiovascular outcome trials (CVOTs) comparing glucagon-like peptide-1 receptor agonists (GLP-1RA) versus placebo on cardiorenal outcomes in patients with type 2 diabetes mellitus (T2DM). Methods: We did an electronic search up to June 30, 2021, for eligible trials. We did a meta-analysis of available trial data using a random-effects model to calculate overall hazard ratios (HRs) and 95% CI (confidence intervals). We included data from 8 CVOTs and 60,080 patients (72.4% with established cardiovascular disease). Results: GLP-1RA reduced major cardiovascular events (MACE) by 14% (HR = 0.86, 95% CI 0.79–0.94, P = 0.006) with a non-significant heterogeneity between subgroups of patients with and without cardiovascular disease (P = 0.127). GLP-1RA also reduced the risk of cardiovascular death by 13% (P = 0.016), nonfatal stroke by 16% (P = 0.007), hospitalization for heart failure by 10% (P = 0.023), all-cause mortality by 12% (P = 0.012), and the broad composite kidney outcome by 17% (P = 0.012), which was driven by a reduction in macroalbuminuria only (HR = 0.74, 0.67–0.82, P < 0.001). Conclusions: GLP-1RA have moderate benefits on MACE, and also reduce hospitalization for heart failure and all-cause mortality; they also have robust benefits on reducing the incidence of macroalbuminuria.

Overview

CoChat Summary

TL;DR

In an updated random-effects meta-analysis of 8 CVOTs and 60,080 patients with type 2 diabetes, GLP-1 receptor agonists reduced MACE by 14% and improved several cardiorenal outcomes, with the largest relative reduction in new macroalbuminuria. Benefits appeared greater in patients with prior cardiovascular disease (16% MACE reduction) than without (6%), but the subgroup interaction was not statistically significant.

Key findings

  • GLP-1RA reduced MACE by 14% overall (HR = 0.86, 95% CI 0.79–0.94, P = 0.006). In 6 CVOTs reporting subgroups, MACE was reduced by 16% in patients with prior CVD (HR = 0.84, 95% CI 0.79–0.90, P < 0.001) and by 6% in those without prior CVD (HR = 0.94, 95% CI 0.83–1.06, P = 0.330), with no significant between-subgroup heterogeneity (P = 0.127).
  • GLP-1RA reduced cardiovascular mortality by 13% (HR = 0.87, 95% CI 0.78–0.96, P = 0.016), nonfatal stroke by 16% (HR = 0.84, 95% CI 0.76–0.94, P = 0.007), hospitalization for heart failure by 10% (HR = 0.90, 95% CI 0.83–0.98, P = 0.023), and all-cause mortality by 12% (HR = 0.88, 95% CI 0.80–0.96, P = 0.012). Nonfatal myocardial infarction showed a nonsignificant 9% decrease (HR = 0.91, 95% CI 0.81–1.01, P = 0.078).
  • In 6 CVOTs, the broad composite kidney outcome was reduced by 17% (HR = 0.83, 95% CI 0.73–0.94, P < 0.012), driven by a reduction in macroalbuminuria only (HR = 0.74, 95% CI 0.67–0.82, P < 0.001), corresponding to a 26% reduction.
  • MACE heterogeneity was I² = 50.0% (P = 0.08); the authors report no major risk of bias in any study.

Methods

  • Systematic review and meta-analysis following PRISMA, searching PubMed, EMBASE, Cochrane Database of Systematic Reviews, and ClinicalTrials.gov up to June 30, 2021. Eligible trials compared GLP-1RA with placebo in adults with T2DM and included cardiorenal outcomes; 8 CVOTs and 3 secondary analyses were included, totaling 60,080 patients (72.4% with established CVD; mean age 64.0 ± 1.97 years; 62.8% male; follow-up 1.3–5.4 years).
  • Random-effects meta-analysis calculated pooled hazard ratios and 95% CIs using the empirical Bayes/Paule-Mandel method with Hartung-Knapp confidence interval adjustment. Heterogeneity was assessed with Cochran’s Q and I²; publication bias was not assessed because fewer than ten trials were included. Analyses used Stata version 16.0.

Limitations

  • The authors state that this is a meta-analysis of aggregate trial data, not patient-level data, which limits subgroup investigation and warrants caution about observed treatment-effect differences between patients with and without pre-existing CVD. They did not explore effects by gender, and note that women are generally underrepresented in CVOTs, potentially reducing statistical power.
  • The authors also state that inclusion/exclusion criteria and endpoint definitions differed slightly across trials, especially for renal endpoints, and that head-to-head trials would be needed to demonstrate possible superiority within the GLP-1RA class. Publication bias was not assessed because the number of trials was below ten.
  • Evident from the text: the protocol was not registered in any platform, all included trials were industry-sponsored, and the small number of trials led to use of a Hartung-Knapp adjustment.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1186/s12933-021-01366-8

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Process of studies’ selection
Fig. 1 Process of studies’ selectionCC BY · PubMed Central
Fig. 2 Cochrane risk of bias (graph) for the 8 trials
Fig. 2 Cochrane risk of bias (graph) for the 8 trialsCC BY · PubMed Central
Fig. 3 Forest plots of meta-analysis of the eight CVOTs with GLP-1RA on MACE. The results are expressed as HR (hazard ratio)
Fig. 3 Forest plots of meta-analysis of the eight CVOTs with GLP-1RA on MACE. The results are expressed as HR (hazard ratio)CC BY · PubMed Central
Fig. 4 Forest plots of meta-analysis of the six CVOTs with GLP-1RA on MACE, in patients with history of CV disease (top) or in patients without such a history (bottom)
Fig. 4 Forest plots of meta-analysis of the six CVOTs with GLP-1RA on MACE, in patients with history of CV disease (top) or in patients without such a history (bottom)CC BY · PubMed Central
Fig. 5 Forest plots of meta-analysis of the eight CVOTs with GLP-1RA on CV mortality
Fig. 5 Forest plots of meta-analysis of the eight CVOTs with GLP-1RA on CV mortalityCC BY · PubMed Central
Fig. 6 Forest plots of meta-analysis of the eight CVOTs with GLP-1RA on nonfatal stroke
Fig. 6 Forest plots of meta-analysis of the eight CVOTs with GLP-1RA on nonfatal strokeCC BY · PubMed Central
Fig. 7 Forest plots of meta-analysis of the eight CVOTs with GLP-1RA on nonfatal myocardial infarction
Fig. 7 Forest plots of meta-analysis of the eight CVOTs with GLP-1RA on nonfatal myocardial infarctionCC BY · PubMed Central
Fig. 8 Forest plots of meta-analysis of the eight CVOTs with GLP-1RA on hospitalization for heart failure
Fig. 8 Forest plots of meta-analysis of the eight CVOTs with GLP-1RA on hospitalization for heart failureCC BY · PubMed Central
Fig. 9 Forest plots of meta-analysis of the eight CVOTs with GLP-1RA on composite renal endpoint
Fig. 9 Forest plots of meta-analysis of the eight CVOTs with GLP-1RA on composite renal endpointCC BY · PubMed Central
Fig. 10 Forest plots of meta-analysis of the eight CVOTs with GLP-1RA on incidence of new macroalbuminuria
Fig. 10 Forest plots of meta-analysis of the eight CVOTs with GLP-1RA on incidence of new macroalbuminuriaCC BY · PubMed Central

Verification

Claims the paper makes

1 Valid · 0 Not valid · 6 Not checked · 24 Own results and interpretations

14 more claims

Create a free account to see all 31 claims and to verify the 9 references still open.

See all claims — free account
  • Probably not a substantial claim. 7
  • The quote only partly states this claim. 1
  • It may state two separate claims as one. 5

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 more claim about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

5 of 7 · the rest aren’t loaded

2 more findings

Create a free account to see every finding of this check.

See all findings — free account

Citations

Cites

Show all 37 references

Cited by

See all 263

Metadata

Authors
Giugliano, D., Scappaticcio, L., Longo, M., Caruso, P., Maiorino, M. I., Bellastella, G., Ceriello, A., Chiodini, P., & Esposito, K.
Affiliations
  • University of Campania "Luigi Vanvitelli" (IT)
  • MultiMedica (IT)
Corresponding author
Giugliano, Dario
Venue
Cardiovascular Diabetology
Published
2021-09-15
Volume
20
Issue
1
Pages
189-189
ISSN
1475-2840 (ISSN-L)
OpenAlex
W3200446817
Cited by
263
References
37
Citations by year
2026: 34 · 2025: 54 · 2024: 66 · 2023: 48 · 2022: 56 · 2021: 5
FWCI
6.75
Type
journal article
Language
en
Open access
Licence
Locations
  • Cardiovascular Diabetology (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
Keywords
GLP-1 receptor agonists, type 2 diabetes, cardiovascular outcome trials, major adverse cardiovascular events, cardiovascular mortality, stroke, heart failure hospitalization, all-cause mortality, renal outcomes, macroalbuminuria, cardiorenal outcomes
MeSH terms
Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Aged, Cardiovascular Diseases, Cause of Death, Clinical Trials as Topic, Diabetes Mellitus, Type 2, Female, Hospitalization, Humans, Hypoglycemic Agents, Kidney Diseases, Male, Middle Aged, Risk Factors, Incidence, Treatment Outcome, Risk Assessment, Incretins, Cardio-Renal Syndrome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-10-04, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-04 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs. https://app.cochat.ai/papers/10.1186/s12933-021-01366-8
The paper
Giugliano, D., Scappaticcio, L., Longo, M., Caruso, P., Maiorino, M. I., Bellastella, G., Ceriello, A., Chiodini, P., & Esposito, K. (2021). GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs. Cardiovascular Diabetology. https://doi.org/10.1186/s12933-021-01366-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.